Cargando…

Critical Analysis of Apixaban Dose Adjustment Criteria

Apixaban is indicated for the prevention of ischemic stroke in non-valvular atrial fibrillation (NVAF), as well as for the prevention and treatment of venous thromboembolism (VTE). Dose adjustment is based on age, weight, and serum creatinine in NVAF, while there are no recommended adjustment criter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vu, Anh, Qu, Tao T., Ryu, Rachel, Nandkeolyar, Shuktika, Jacobson, Alan, Hong, Lisa T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175828/ https://www.ncbi.nlm.nih.gov/pubmed/34075813 http://dx.doi.org/10.1177/10760296211021158

Ejemplares similares

Response to “Critical Analysis of Apixaban Dose Adjustment Criteria”
por: Mandt, Stephen R., et al.
Publicado: (2022)

A Case of Delayed Hemorrhagic Effusive-Constrictive Pericarditis After Left Atrial Appendage Occlusion Device Placement
por: Nandkeolyar, Shuktika, et al.
Publicado: (2019)

The Problem With Predictions: A Cautionary Tale of Empirically Adjusting Apixaban Dosing With Carbamazepine
por: Chadha, Ayush, et al.
Publicado: (2022)

Case Illustrations of the Utility of Echocardiography in Gunshot Wound Trauma
por: Nandkeolyar, Shuktika, et al.
Publicado: (2021)

Keeping pace: A 38-second ictal asystole revealed during simultaneous electroencephalogram and electrocardiogram monitoring
por: Nandkeolyar, Shuktika, et al.
Publicado: (2017)

Torsades de Pointes due to Excessive Marijuana Use in a Susceptible Patient
por: Shah, Vivek D., et al.
Publicado: (2021)

In-hospital Initiation and Up-titration of Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction
por: Cox, Zachary L, et al.
Publicado: (2022)

Trial of Oral Diuretics Prior to Discharge Is Not Associated With Improved Outcomes in Decompensated Heart Failure
por: Mohammad, Adeba, et al.
Publicado: (2021)

Predictors of In-hospital Mortality in Cardiogenic Shock Patients on Vasoactive or Inotropic Support
por: Nandkeolyar, Shuktika, et al.
Publicado: (2021)

Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban
por: Frost, Charles E., et al.
Publicado: (2015)

A Multidisciplinary Approach to Electrical Instability and Cardiogenic Shock in Acute Myocardial Infarction
por: Nandkeolyar, Shuktika, et al.
Publicado: (2020)

Apixaban-Induced Hepatotoxicity
por: Ansari, Umair, et al.
Publicado: (2022)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
por: Cui, Yimin, et al.
Publicado: (2013)

Microtubules that form the stationary lattice of muscle fibers are dynamic and nucleated at Golgi elements
por: Oddoux, Sarah, et al.
Publicado: (2013)

Apixaban Dosing in Patients With Kidney Failure Treated With Peritoneal Dialysis
por: Lidgard, Benjamin, et al.
Publicado: (2023)

Preparation of Apixaban Solid Dispersion for the Enhancement of Apixaban Solubility and Permeability
por: Lee, Juseung, et al.
Publicado: (2023)

DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa (Apixaban) and INVICTUS (Rivaroxaban)
por: Ryu, Rachel
Publicado: (2022)

Apixaban and oral implications
por: Lopez-Galindo, Monica, et al.
Publicado: (2015)

Effectiveness and safety of low-dose versus standard-dose rivaroxaban and apixaban in patients with atrial fibrillation
por: Perreault, Sylvie, et al.
Publicado: (2022)

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects
por: Frost, Charles, et al.
Publicado: (2018)

Apixaban: Haematochezia: case report
Publicado: (2021)

Apixaban-Induced Skin Purpura
por: Rodríguez, Miryam Moreta, et al.
Publicado: (2021)

Implications of apixaban for dental treatments
por: Curto, Adrian, et al.
Publicado: (2016)

Quick reference guide to apixaban
por: Hurst, Katherine Victoria, et al.
Publicado: (2017)

A case report of heart transplant for ischaemic cardiomyopathy from lupus coronary vasculitis
por: Nandkeolyar, Shuktika, et al.
Publicado: (2019)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
Publicado: (2014)

Pharmacokinetics of Apixaban Among Peritoneal Dialysis Patients
por: Fung, Winston Wing-Shing, et al.
Publicado: (2023)

The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
por: Frost, Charles, et al.
Publicado: (2017)

Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways
por: Huppertz, Andrea, et al.
Publicado: (2019)

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
por: Frost, Charles, et al.
Publicado: (2013)

Apixaban: Skin manifestations: case report
Publicado: (2021)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Apixaban: Gastrointestinal bleeding: case report
Publicado: (2021)

Apixaban: Treatment failure: case report
Publicado: (2021)

A Dangerous and Unrecognized Interaction of Apixaban
por: Ammar, Hussam, et al.
Publicado: (2021)

The new factor Xa inhibitor: Apixaban
por: Bhanwra, Sangeeta, et al.
Publicado: (2014)

Quick reference guide to apixaban [Corrigendum]
Publicado: (2017)

The use of Apixaban for the treatment of an LV thrombus
por: Bennett, Sadie, et al.
Publicado: (2018)

Atraumatic splenic rupture associated with apixaban
por: Basnet, Sijan, et al.
Publicado: (2019)

Case report: apixaban‐induced thrombocytopenia
por: Snellgrove, Oliver
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dicbjpc364r9ulvs8240099bps